Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04240522

Prospective Longitudinal Observational Research in Atopic Dermatitis

Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march.

Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality.

This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich

Zurich, Canton of Zurich, 8091, Switzerland

Location status: Recruiting

Location contact

Marie-Charlotte Brueggen, Prof, MD

CONTACT

[email protected]

+41 43 253 10 75

About this study

Primary Objetive:

In the planned project, the main objective is to identify endogenous (e.g. immunological and molecular factors) and exogenous factors (e.g. environmental, socioeconomic and microbial factors) that influence the course and remission of AD. More specifically to identify factors that are significantly different between patients that have or do not have remission from AD.

Secondary Objective:

(i) To identify endogenous and exogenous factors such as immunological, molecular and microbial factors to separate subgroups of patients (endotypes) with distinct local and systemic inflammatory responses.

(ii) To identify potential biomarkers predicting the individual clinical course of AD and other atopic diseases including asthma, food allergy and allergic rhinitis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 0 - 85 years
  • Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy)
  • The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated

The inclusion criteria for healthy controls in this study are as follows:

  • Age 0 - 85 years
  • No diagnosis or history of allergic disease
  • The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated

Written consent will be obtained after detailed information of the study was given to the participant.

Exclusion criteria

  • Unable to give consent or refusal to participate in the study

Treatment and study plan

Primary outcomes

  1. Remission of atopic dermatitis and associated allergic diseases

    Time frame: 5 years

    Prospective observational study

Secondary outcomes

  1. Endogenous and exgogenouse factors that influence and predict the course of AD.

    Time frame: 5 years

    Prospective observational study

  2. Identification of potential biomarkers predicting the course of AD

    Time frame: 5 years

    Prospective observational study

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • University of Bonn

Registry information

Official study title

Prospective Longitudinal Observational Research Study to Investigate the Remission of Atopic Dermatitis and Associated Allergic Diseases

Acronym: ProRaD

Important dates

Study start
2017
Primary completion
2031
Study completion
2031
First posted
Jan 27, 2020
Registry last updated
Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.